Galderma deprioritizes study for IL-31 drug; UCB stops work in rare encephalitis

Plus, news about GlycoMimetics and Indivior:

Galderma stops plans to develop nemolizumab in Phase 2: The Swiss dermatology company said it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Private equity activity in the pharmaceutical industry in China increased in 2023

In value terms, private equity deal activity in China remained flat in Q2 2023 compared with the previous quarter and as compared to Q2 2022.

August 1, 2023

Imported case of monkeypox leads to local transmission in China

Monkeypox (mpox) is a zoonotic disease caused by the mpox virus (MPXV) that has been primarily limited to Central and West African nations since its

September 15, 2023

Golden Hour Bundle of Interventions Boosts Outcomes for High-Risk Preterm Infants

WASHINGTON — A multidisciplinary quality improvement (QI) team successfully and safely adhered to a golden hour bundle of interventions for high-risk preterm infants, a researcher

October 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.